| Code | Description | Claims | Beneficiaries | Total Paid |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,428 |
6,070 |
$309K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,894 |
2,301 |
$64K |
| 94060 |
|
793 |
605 |
$21K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
800 |
174 |
$20K |
| 93922 |
|
536 |
388 |
$19K |
| 71047 |
|
641 |
499 |
$10K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
760 |
578 |
$6K |
| 93923 |
|
118 |
93 |
$6K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
58 |
58 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
1,446 |
1,214 |
$5K |
| 93000 |
|
299 |
216 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
248 |
162 |
$3K |
| 99252 |
|
35 |
33 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
58 |
58 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
29 |
25 |
$1K |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
853 |
636 |
$828.80 |
| 70210 |
|
36 |
36 |
$539.70 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
16 |
14 |
$452.30 |
| 70220 |
|
17 |
17 |
$424.84 |
| 80305 |
|
34 |
30 |
$274.92 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16 |
14 |
$115.83 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
16 |
14 |
$112.05 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
24 |
13 |
$90.87 |
| 96127 |
|
24 |
14 |
$80.07 |
| 80061 |
Lipid panel |
76 |
71 |
$72.82 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
22 |
12 |
$43.94 |